A Phase 1 Safety Study of COVID-19 Vaccine (TNX-1800) in Humans

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 13 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Nov 2023 According to a Tonix Pharmaceuticals Inc media release, NIAID will cover the full cost of the clinical trial, including operations and related analysis.Tonix will be responsible for providing clinical trial materials, and upon completion will have the right to rely on the findings in regulatory filings with the U.S. Food and Drug Administration (FDA) to support the approval of its COVID-19 vaccine and other vaccines based on the RPV platform.
02 Nov 2023 According to a Tonix Pharmaceuticals Inc media release, the company announced that the National Institute of Allergy and Infectious Diseases (NIAID), will conduct a Phase 1 clinical trial with TNX-1800, NIAID will study TNX-1800 by percutaneous administration.
02 Nov 2023 According to a Tonix Pharmaceuticals Inc media release, Phase 1 clinical trial of TNX-1800 expected to start in the second half of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com